Results 41 to 50 of about 12,945 (221)

Kaposiform hemangioendothelioma: Diagnosis and treatment

Pediatric Investigation, EarlyView.
Vascular endothelial growth factor‐C (VEGF‐C)/vascular endothelial growth factor receptor‐3 (VEGFR‐3) and angiopoietin‐2 (Ang‐2)/tyrosine kinase with immunoglobulin‐like and EGF‐like domain 2 (TIE2) signaling pathways play an important role in lymphangiogenesis.
Yi Tian, Yuanyuan Tian, Li Wei, Zigang Xu, Li Li, Lin Ma   +5 more
wiley   +1 more source

Development and Validation of the Japanese Version of the Hyperhidrosis Quality of Life Index

The Journal of Dermatology, EarlyView.
ABSTRACT Hyperhidrosis decreases an individual's quality of life (QOL). The Hyperhidrosis Quality of Life Index (HidroQoL) measures the impact of hyperhidrosis on QOL and has established reliability and validity. However, a Japanese version does not exist.
Sayaka Ogawa, Jun Tayama, Paul Kamudoni, Sam Salek, Peter Bernick, Masakazu Kobayashi, Seiko Nakamichi, Hiroyuki Murota   +7 more
wiley   +1 more source

Interventions for hyperhidrosis in secondary care: a systematic review and value-of-information analysis

Health Technology Assessment, 2017
Background: Hyperhidrosis is uncontrollable excessive sweating that occurs at rest, regardless of temperature. The symptoms of hyperhidrosis can significantly affect quality of life. The management of hyperhidrosis is uncertain and variable.
Ros Wade, Stephen Rice, Alexis Llewellyn, Eoin Moloney, Julie Jones-Diette, Julija Stoniute, Kath Wright, Alison M Layton, Nick J Levell, Gerard Stansby, Dawn Craig, Nerys Woolacott   +11 more
doaj   +1 more source

Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once‐weekly dosing that supports adherence. However, injection‐site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause ...
Shifa Taj, Mohammed Zuber, Muhammed Rashid, Manik Chhabra, Krishna Undela, Smita Rawal, Lorenzo Villa Zapata   +6 more
wiley   +1 more source

Objective evaluation of plantar hyperhidrosis after sympathectomy

Clinics, 2013
OBJECTIVE: The aim of the present study was to prospectively, randomly, blindly, and objectively investigate how surgery affects plantar sudoresis in patients with palmar and plantar hyperhidrosis over a one-year period using a sudorometer (VapoMeter ...
Nelson Wolosker, Augusto Ishy, Guilherme Yazbek, Jose Ribas Milanez de Campos, Paulo Kauffman, Pedro Puech-Leão, Fabio Biscegli Jatene   +6 more
doaj  

The quality of life and satisfaction rate of patients with upper limb hyperhidrosis before and after bilateral endoscopic thoracic sympathectomy

Saudi Journal of Anaesthesia, 2019
Background: Hyperhidrosis is a functional disorder identified by excessive sweating. Its incidence is approximately 1% in any population. Bilateral endoscopic thoracic sympathectomy (BETS) intervention is the definitive treatment of choice for palmar and
Waseem M Hajjar, Sami A Al-Nassar, Heba M Al-Sharif, Dana M Al-Olayet, Wejdan S Al-Otiebi, Alanoud A Al-Huqayl, Adnan W Hajjar   +6 more
doaj   +1 more source

Efficacy and safety of switching basal insulin to insulin glargine 300 U/mL in individuals with inadequately controlled type 2 diabetes on advanced insulin therapies: The Toujeo‐Neo T2DM study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This real‐world study evaluated the effectiveness and safety of switching basal insulin (BI) to insulin glargine 300 U/mL (Gla‐300) in adults with inadequately controlled type 2 diabetes mellitus (T2DM), previously receiving basal‐supported oral therapy plus prandial insulin (BOTplus) or multiple (≥3) daily injections (MDI) of short ...
Stefan Pscherer, Andreas Fritsche, Helmut Anderten, Katrin Pegelow, Henry Y. Han, Martin Pfohl, Jochen Seufert   +6 more
wiley   +1 more source

Pharmacokinetics and adverse effects of a long‐acting IM dopamine agonist: Cabergoline in healthy horses

Equine Veterinary Education, EarlyView.
Summary Background Pituitary pars intermedia dysfunction (PPID) is commonly treated with pergolide mesylate, a dopamine receptor agonist. Cabergoline is a dopamine receptor agonist that has shown activity on prolactin secretion in horses for up to 10 days.
H. Hess, A. Bracken, S. Rao, Y. Nout‐Lomas, D. Gustafson, L. Bass   +5 more
wiley   +1 more source

A Study on the Impact of Hyperhidrosis on the Quality of Life among College Students [PDF]

Journal of Clinical and Diagnostic Research, 2016
Introduction: Hyperhidrosis (HH) is a condition characterized by excessive sweating or perspiration. General population, especially in developing countries like India are seldom aware of this condition and sparsely seek medical attention. The tropical
Anbarasi Muthusamy, Rajkumar Gajendran, Sathasivam Ponnan, Dinesh Thangavel, Venkatesan Rangan   +4 more
doaj   +1 more source

The HRAS Variant c.175G>A (p.Ala59Thr) Causes a Predominantly Ectodermal Phenotype Lacking Classic Costello Syndrome Features

American Journal of Medical Genetics Part A, Volume 200, Issue 2, Page 407-418, February 2026.
ABSTRACT Costello syndrome (CS) is a rare dominant HRAS RASopathy characterized by curly hair, cardiac abnormalities, craniofacial anomalies, and developmental delay. HRAS codon 58, 59, and 60 variants are associated with milder phenotypes. We describe a three‐generation family with a previously unreported heterozygous HRAS variant c.175G>A (p.Ala59Thr)
Nikole Rautiainen, Eveliina Brandt, Kaisa Kettunen, Outi Elomaa, Sirpa Kivirikko, Leila Jeskanen, Katriina Lappalainen, Nelli Sjöblom, Juha Kere, Katariina Hannula‐Jouppi, Liisa Harjama   +10 more
wiley   +1 more source